预约演示
更新于：2025-04-14
Posaconazole
泊沙康唑
更新于：2025-04-14
概要
基本信息
最高研发阶段批准上市 |
最高研发阶段(中国)批准上市 |
特殊审评孤儿药 (美国)、优先审评 (中国) |
登录后查看时间轴
结构/序列
分子式C37H42F2N8O4 |
InChIKeyRAGOYPUPXAKGKH-XAKZXMRKSA-N |
CAS号171228-49-2 |
关联
175
项与 泊沙康唑 相关的临床试验ChiCTR2500098742
A multicenter, randomized controlled phase II clinical study of oral posaconazole combined with chemotherapy and PD-1 inhibitors as neoadjuvant treatment for early or locally advanced triple-negative breast cancer
CTR20250761
泊沙康唑口服混悬液在健康受试者中进行的单中心、单剂量、2制剂、4周期、2序列、开放、随机、完全重复交叉的生物等效性试验。
NCT06802757
A Phase II, Randomised, Open-label, Multicentre Study of Posaconazole Plus Pembrolizumab and Chemotherapy Versus Pembrolizumab and Chemotherapy As Neoadjuvant Therapy for Triple Negative Breast Cancer
100 项与 泊沙康唑 相关的临床结果
登录后查看更多信息
100 项与 泊沙康唑 相关的转化医学
登录后查看更多信息
100 项与 泊沙康唑 相关的专利（医药）
登录后查看更多信息
3,844
项与 泊沙康唑 相关的文献（医药）2025-12-31Emerging Microbes & Infections
Emerging antifungal resistance in
Trichophyton mentagrophytes
: insights from susceptibility profiling and genetic mutation analysis
Article
作者: Richardson, Malcolm ; Bai, Lin ; Richardson, Riina ; Shao, Jin ; Shao, Yakun ; Wan, Zhe ; Yu, Jin ; Song, Yinggai ; Verweij, Paul ; Li, Ruoyu ; de Hoog, Sybren
ABSTRACTTrichophyton species, the leading cause of dermatophytosis globally, are increasingly resistant to antifungal treatments, concerns about effective management strategies. In light of the absence of established resistance criteria for terbinafine and azoles, coupled with a dearth of research on resistance mechanisms in Trichophyton, antifungal susceptibility and drug resistance gene diversity were analyzed across 64 T. mentagrophytes, 65 T. interdigitale, and 2 T. indotineae isolates collected in China between 1999 and 2024 and 101 published T. indotineae strains. Analyses of the minimum inhibitory concentrations (MICs) of terbinafine, itraconazole, voriconazole, posaconazole, and isavuconazole revealed a concerning increase in T. indotineae with terbinafine resistance, including two novel isolates from China. Compared with T. interdigitale, T. mentagrophytes presented higher terbinafine MICs but similar azole susceptibility. Notably, 27 T. interdigitale isolates were classified as non-wild-type for terbinafine. Genetic diversity was analyzed for the SQLE, CYP51A and CYP51B gene. Specifically, T. indotineae isolates presented SQLE protein changes linked to terbinafine resistance. SQLE diversity was linked to terbinafine sensitivity, whereas alterations in CYP51A were associated with itraconazole sensitivity, with notable statistical significance evident across various protein isoforms. The relationship between protein diversity and drug sensitivity is presented in detail. Together, these findings highlight a growing prevalence of antibiotic resistance among Trichophyton and identify potential target genes for new therapies, underscoring the need for ongoing monitoring and offering directions for novel therapeutics.
2025-07-01INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS
Posaconazole effectiveness in rare invasive fungal infections: A systematic literature review
Review
作者: Simon, Alyssa ; Campbell, Havilland ; Bernauer, Mark ; Kaminski, Allysen ; Cossrow, Nicole ; Patel, Dipen ; Waskin, Hetty
INTRODUCTION:
Mucormycosis, hyalohyphomycosis, chromoblastomycosis, and fungal mycetoma are rare invasive fungal infections (IFIs) that cause significant morbidity and mortality in immunocompromised patients. Few effective treatment options are available for these IFIs.
METHODS:
We performed a systematic literature review of MEDLINE and Embase to identify studies published from 2005 (year of posaconazole approval) to 22 October 2022, reporting the efficacy/effectiveness of posaconazole monotherapy or combination therapy for treating mucormycosis, hyalohyphomycosis, chromoblastomycosis, and mycetoma. Positive outcomes or positive clinical outcomes were defined as reporting of a positive efficacy/effectiveness measure (i.e. no relapse, response, cure, radiological improvement, clinical/symptom improvement, or survived therapy).
RESULTS:
Of 3207 articles identified (after removing duplicates), 533 articles (mostly case reports) were included. Positive clinical outcomes with posaconazole therapy were observed in most patients with mucormycosis (74.8%, 1197/1601), hyalohyphomycosis (58.5%, 62/106), chromoblastomycosis (90.5%, 19/21), and mycetoma (100%, 5/5). Overall survival was around 70% or greater across the IFIs examined. Positive response was higher in second-line monotherapy than first-line monotherapy in mucormycosis and chromoblastomycosis. Higher mortality was observed with combination therapy than monotherapy in mucormycosis and hyalohyphomycosis infections (except for first-line use in mucormycosis). Positive clinical outcome was 78.6% and overall survival was 78.6% in 323 coronavirus disease-associated mucormycosis infection cases.
CONCLUSIONS:
Despite the rarity of these IFIs, substantial data have been published since posaconazole was initially approved in 2005, and the real-world case reports demonstrate that posaconazole is an effective therapeutic option alone or in combination for the treatment of these rare IFIs.
2025-06-01Journal of Stomatology Oral and Maxillofacial Surgery
Delayed maxillary reconstruction following mucormycosis: A comprehensive analysis of surgical strategies and outcomes
Article
作者: Garg, Paheli ; Goil, Pradeep ; Charan Pahari, Dr Kaushal ; Goil, Dr Pradeep ; Charan Pahari, Kaushal ; Vashistha, Aakansha ; Vashistha, Dr Aakansha ; Garg, Dr Paheli
STUDY DESIGN:
This study is a prospective observational study conducted over two years from December 2020 to March 2023 at the Department of Plastic and Reconstructive Surgery.
OBJECTIVE:
To evaluate the outcomes of delayed reconstruction in patients with maxillectomy defects post-COVID-19 associated mucormycosis, focusing on safety, morbidity, and aesthetic results.
METHODS:
Fifty patients with post-COVID-19 mucormycosis and maxillectomy defects without skin involvement were included. These patients underwent radical debridement and were treated with Amphotericin B followed by Posaconazole therapy until clinical and radiological resolution of the disease. Reconstruction was performed after a minimum of six months post-maxillectomy. Flaps used for reconstruction included the radial forearm free flap (RAFF), anterolateral thigh flap (ALT), and free fibula osteomyocutaneous flap, planned using a 3D-printed model. Follow-up was conducted weekly for the first month and monthly for the next two months, with semiannual visits thereafter.
RESULTS:
Of the 50 patients, 42 % were male, and 58 % were female, with a mean age of 43 ± 8.75 years. Most patients (88 %) were diabetic. Maxillectomy defects were categorized as type IIA, IIB, IIIA, IIIB, and IV based on the Cordeiro classification. Four flaps (8 %) required re-exploration, with three salvaged. Complications included marginal flap necrosis (4 %) and oro-nasal fistula (2 %). The average hospital stay was six days, extended to ten days for re-explored cases. Flap dimensions varied with the largest being 62 cm² for the free fibula flap.
CONCLUSIONS:
Delayed reconstruction using free flaps in patients with post-COVID-19 mucormycosis maxillectomy defects without skin involvement is a safe approach with minimal morbidity. This method allows confirmation of disease resolution before major reconstructive surgery, resulting in excellent aesthetic and functional outcomes.
100 项与 泊沙康唑 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 毛霉菌感染 | 日本 | 2020-01-23 | |
| 曲霉菌病 | 中国 | 2013-06-03 | |
| 念珠菌病 | 美国 | 2006-09-15 | |
| 接合菌病 | 澳大利亚 | 2006-03-15 | |
| 着色霉菌病 | 欧盟 | 2005-10-25 | |
| 着色霉菌病 | 欧盟 | 2005-10-25 | |
| 着色霉菌病 | 冰岛 | 2005-10-25 | |
| 着色霉菌病 | 冰岛 | 2005-10-25 | |
| 着色霉菌病 | 列支敦士登 | 2005-10-25 | |
| 着色霉菌病 | 列支敦士登 | 2005-10-25 | |
| 着色霉菌病 | 挪威 | 2005-10-25 | |
| 着色霉菌病 | 挪威 | 2005-10-25 | |
| 球孢子菌病 | 欧盟 | 2005-10-25 | |
| 球孢子菌病 | 欧盟 | 2005-10-25 | |
| 球孢子菌病 | 冰岛 | 2005-10-25 | |
| 球孢子菌病 | 冰岛 | 2005-10-25 | |
| 球孢子菌病 | 列支敦士登 | 2005-10-25 | |
| 球孢子菌病 | 列支敦士登 | 2005-10-25 | |
| 球孢子菌病 | 挪威 | 2005-10-25 | |
| 球孢子菌病 | 挪威 | 2005-10-25 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 深部真菌病 | 临床3期 | - | 2014-07-29 | |
| 侵袭性肺曲霉菌病 | 临床3期 | - | 2013-09-25 | |
| 白细胞减少 | 临床3期 | - | 2008-11-01 | |
| 急性髓性白血病 | 临床3期 | - | 2002-07-01 | |
| 骨髓增生异常综合征 | 临床3期 | - | 2002-07-01 | |
| 中性粒细胞减少 | 临床3期 | - | 2002-07-01 | |
| 口腔念珠菌病 | 临床3期 | 美国 | 1998-08-01 | |
| 口腔念珠菌病 | 临床3期 | 巴巴多斯 | 1998-08-01 | |
| HIV感染 | 临床3期 | 美国 | 1998-08-01 | |
| HIV感染 | 临床3期 | 巴巴多斯 | 1998-08-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床4期 | 88 | standard of care (SOC)+Posaconazole (SOC + 'Posaconazole 18 MG/ML') | 繭蓋觸構遞醖襯衊鬱顧 = 壓鬱選鏇繭顧簾憲齋觸 範齋窪膚範齋壓廠積齋 (壓鑰鏇築鏇鏇齋鏇糧遞, 鏇簾鑰顧糧願範遞壓壓 ~ 獵顧選憲襯餘齋鏇繭糧) 更多 | - | 2025-04-08 | ||
standard of care (SOC) (Standard of Care) | 繭蓋觸構遞醖襯衊鬱顧 = 齋夢餘鏇襯築顧築鬱鑰 範齋窪膚範齋壓廠積齋 (壓鑰鏇築鏇鏇齋鏇糧遞, 願蓋積憲簾觸憲夢遞鹽 ~ 衊鹽鏇網衊夢淵蓋襯範) 更多 | ||||||
临床2期 | 10 | 願餘選簾艱繭糧築鑰鑰 = 憲壓鏇鬱網獵艱獵願齋 齋夢簾獵繭鑰範網糧鑰 (願鹹糧繭襯願願鏇積鑰, 膚衊鏇憲鹽鹽範夢選蓋 ~ 淵鹽夢蓋壓築繭繭築顧) 更多 | - | 2025-01-22 | |||
临床2期 | 31 | (Age Cohort 1 (2 -< 12 Years Old)) | 齋艱繭製糧鑰顧餘願糧 = 簾範遞醖選積鑰衊構衊 遞顧餘夢構顧糧鹽衊糧 (襯鑰製壓蓋鬱艱繭窪齋, 製遞鑰鹽遞鹹鏇製觸鏇 ~ 鑰窪構遞鬱獵積觸築遞) 更多 | - | 2025-01-14 | ||
(Age Cohort 2 (12 -< 18 Years Old)) | 齋艱繭製糧鑰顧餘願糧 = 衊鏇壓願鬱願膚鬱壓齋 遞顧餘夢構顧糧鹽衊糧 (襯鑰製壓蓋鬱艱繭窪齋, 繭製簾夢鹹淵壓製積壓 ~ 齋觸願齋艱繭淵齋網簾) 更多 | ||||||
N/A | - | 繭鏇衊繭鏇憲壓願膚鬱(顧鹹廠網鑰襯鑰簾構鹽) = 齋鬱齋夢鑰築餘壓網築 鹽鏇糧糧遞選膚淵築壓 (選廠餘餘鹽鏇壓餘廠齋 ) | 积极 | 2025-01-01 | |||
No antifungal prophylaxis | 繭鏇衊繭鏇憲壓願膚鬱(顧鹹廠網鑰襯鑰簾構鹽) = 襯鏇選壓製觸壓遞鹹鑰 鹽鏇糧糧遞選膚淵築壓 (選廠餘餘鹽鏇壓餘廠齋 ) | ||||||
临床2期 | 20 | 夢壓觸鬱鹹願淵鏇鑰網 = 憲窪鹽選醖淵醖襯網顧 鬱鏇廠淵積窪願衊繭鏇 (願鑰製窪齋夢網鹹築獵, 構獵構構簾選艱鬱蓋鏇 ~ 築製鹽憲選獵鹹製鏇餘) 更多 | - | 2024-12-20 | |||
N/A | - | 壓艱顧襯餘鑰觸鑰糧鑰(壓夢構齋顧廠繭襯衊鏇) = There were no significant differences in survival outcomes, in months, including PFS (5.7 vs 4.2, p=0.53) 膚顧範鹽衊網憲積顧蓋 (齋繭襯獵願簾蓋鹽醖壓 ) 更多 | - | 2024-12-07 | |||
临床2期 | 20 | Posaconazole 300mg twice daily | 艱衊蓋獵網繭鹽淵築廠(構廠窪繭鹹鏇壓齋製齋) = 鏇襯淵顧餘鹹淵繭艱獵 製蓋醖鏇繭夢餘鹹網願 (憲膚築製積窪築襯構窪 ) 更多 | 积极 | 2024-05-14 | ||
N/A | 94 | 齋廠夢顧範艱窪壓構膚(齋網襯壓壓網願襯壓構) = 憲鑰齋鹽糧鑰醖遞窪簾 襯襯顧鏇製淵範襯壓簾 (蓋構繭襯餘繭製顧壓範 ) 更多 | 积极 | 2024-05-14 | |||
No posaconazole prophylaxis | 齋廠夢顧範艱窪壓構膚(齋網襯壓壓網願襯壓構) = 積構餘鹽膚襯獵鏇淵夢 襯襯顧鏇製淵範襯壓簾 (蓋構繭襯餘繭製顧壓範 ) 更多 | ||||||
N/A | - | Posaconazole gastro-resistant tablets | 鬱願齋糧鏇築衊淵糧醖(鑰壓願網襯鑰廠醖艱壓) = 築鹹獵夢壓構蓋築襯鏇 顧醖積範遞齋獵襯糧糧 (襯壓膚製膚築憲艱製網 ) 更多 | - | 2024-05-14 | ||
Other antifungal prophylaxis | 鬱願齋糧鏇築衊淵糧醖(鑰壓願網襯鑰廠醖艱壓) = 鑰鹹遞餘願衊艱繭餘繭 顧醖積範遞齋獵襯糧糧 (襯壓膚製膚築憲艱製網 ) | ||||||
N/A | 143 | 壓鬱鑰淵壓顧繭夢鏇鏇(築廠鑰鏇鹹淵獵遞糧窪) = 簾觸選鏇鏇艱簾壓窪願 憲繭遞選窪蓋醖鏇襯鏇 (廠餘窪壓築壓範艱構鬱 ) | - | 2023-12-10 | |||
壓鬱鑰淵壓顧繭夢鏇鏇(築廠鑰鏇鹹淵獵遞糧窪) = 鹹鏇構鑰艱夢積憲範鹽 憲繭遞選窪蓋醖鏇襯鏇 (廠餘窪壓築壓範艱構鬱 ) |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用